Skip to content
Storytelling Co – Lifestyle
Author:
PMGC Holdings Inc.
PMGC Holdings Inc. [NASDAQ: ELAB] Reports Record Q3 Revenue, Up 785% Year-over-Year to $2.53 Million and Up 94% From Previous Quarter; Files Form 10-Q for Q3 2026; Total Assets of $133.1 Million Include $100.4 Million Held in Trust by Sponsored SPAC
November 16, 2026
PMGC Holdings Inc. Announces Strategic Share Acquisition in Australian Space Technology Company Orbit2Orbit
November 10, 2026
NorthStrive Biosciences Announces Results from EL-32 Preclinical Combination Study with Semaglutide and Plans for Next Phase of Development
November 5, 2026
PMGC Holdings Inc. Announces DBA as NorthStrive Holdings, Inc., Trademark License Agreement, and Website Update
October 8, 2026
PMGC Holdings (Nasdaq: ELAB) Announces Completion of $100 Million SPAC IPO, Launching NorthStrive Acquisition Corp. I (Nasdaq: NSAI) as First in Planned SPAC Sponsorship Franchise to Expand M&A Strategy
October 1, 2026
NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs
September 29, 2026
PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings
September 18, 2026
NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications
September 1, 2026
PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio
August 26, 2026
PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss
August 25, 2026
1
2
3
Next Page
→